PathGroup Partners with Vistapath to Advance Laboratory Precision and Efficiency with AI-Powered Grossing 

BOSTON and NASHVILLE – [13 Nov 2025] – Vistapath, a leader in pathology automation and AI-driven laboratory solutions, announced that PathGroup will deploy its Sentinel AI-powered grossing platform at PathGroup’s centralized laboratory in Nashville, TN. The rollout of twelve Sentinel units will strengthen PathGroup’s commitment to innovation, diagnostic precision, and operational excellence. 

PathGroup’s adoption of Sentinel marks a major step forward in modernizing the grossing process – one of the most labor-intensive stages of pathology. The platform leverages advanced computer vision and machine learning to standardize specimen handling, enhance traceability, and deliver real-time quality assurance, empowering laboratory teams to work more efficiently and consistently. 

“As PathGroup continues to adopt best-in-class novel technology, we are very excited to be partnering with Vistapath for the use of their Sentinel device and the associated algorithms and applications. The use of the Sentinel device in our high-volume grossing facilities will provide transformative workflow, as well as enhanced report integrity and quality. The Vistapath solution is a very logical supplement to our fully digital slide scanning operations, and the capabilities that Tim and his team have created are very impressive” – Derek Welch, President and CMO, PathGroup 

Sentinel seamlessly integrates with laboratory information systems (LIS) and existing digital pathology workflows to capture, analyze, and document grossing data. By applying AI to specimen processing, it helps pathologists and lab professionals reduce variability, optimize turnaround times, and ensure that every sample contributes to accurate downstream diagnoses. 

“The Vistapath team is excited to provide PathGroup access to our AI-enabled grossing station, the Vistapath Sentinel, and SentinelOS, our suite of pathology workflow tools. We have long admired PathGroup’s commitment to technology that improves care for patients, pathologists, and providers.  Our collaboration with PathGroup represents an important step forward in achieving our shared objectives of modernizing pathology and improving the care of patients we serve.” – Tim Spong, CEO, Vistapath 

The partnership reinforces PathGroup’s continued investment in next-generation technologies that elevate diagnostic quality and laboratory productivity. By introducing Sentinel, PathGroup is paving the way for broader AI adoption in anatomic pathology and setting a new standard for how laboratories integrate automation to support clinicians and patients alike. 

About PathGroup 

Founded in 1965, PathGroup is a premier provider of anatomic, clinical, molecular, and digital pathology services in the United States. As a physician-led practice, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships. PathGroup uses the latest in proprietary and industry standard technology, including an industry-leading deployment of digital pathology across its organization, to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers, and most importantly, patients. PathGroup is more than a laboratory – it is a trusted partner in health, driven by a mission to improve lives through diagnostic excellence and innovation. For more information, visit https://www.pathgroup.com/. 

VistaPath, the leading provider of artificial intelligence (AI)-based, data-driven pathology processing platforms, today announced that VistaPath Sentinel was validated in a clinical setting after a collaboration with PathAI, a global leader in AI-powered pathology. VistaPath Sentinel is the world’s first automated tissue grossing platform.

The Sentinel is a first-of-its-kind tissue grossing platform that automates the process of receiving, assessing, and processing tissue samples. Designed to make tissue grossing faster, safer, and easier, the Sentinel uses a high-quality video system to assess specimens and create a gross report 93% faster than human technicians with 43% more accuracy. It not only improves on quality by continuously monitoring the cassette, container, and tissue to reduce mislabeling and specimen mix-up, but also increases traceability by retaining original images for downstream review.

“Despite informing a majority of clinical decisions, anatomical pathology still prepares samples for diagnosis manually, in stark contrast to other clinical lab services. Our work with PathAI has proven our ability to modernize this critical lab process,” said Timothy Spong, CEO of VistaPath. “This is a complimentary partnership of AI technologies. PathAI’s validation of the Sentinel in a clinical setting has charted the course for broader use of the device in the clinical market, following our FDA and ISO27001 compliance earlier this year.”

For customers like PathAI, the Sentinel adds another level of sophistication to their workflow by providing automated grossing, making the process faster, cheaper and with fewer errors. “We joined with a top anatomic pathology laboratory to establish a new type of modern lab, PathAI Diagnostics. This commitment to usher in a new era of precision pathology requires partners that can transform other parts of the laboratory process outside of the diagnosis itself; VistaPath offers a technology that can automate grossing,” said Dr. Andy Beck, CEO and Co-Founder of PathAI. “Implementing the Sentinel into our clinical workflow can tremendously impact our diagnostic laboratory process management with a high-quality, AI-focused solution.”